Abstract LB001: Anti-tumor activity and tolerability of the SHP2 inhibitor RMC-4630 as a single agent in patients with RAS-addicted solid cancers
Marianna Koczywas(City Of Hope National Medical Center), Sai‐Hong Ignatius Ou(University of California, Irvine Medical Center), Caroline E. McCoach(Memorial Sloan Kettering Cancer Center), Luxi Yang(Memorial Sloan Kettering Cancer Center), Richa Dua(Revolution Medicines (United States)), Susanna V. Ulahannan(Oklahoma State University Oklahoma City), Pasi A. Jänne(Harvard University), Eric B. Haura(Moffitt Cancer Center), Michael S. Gordon(Pinnacle Oncology Hematology), Howard A. Burris(Deaconess Hospital), Jonathan W. Riess(University of California Davis Medical Center), Josie Hayes(University of California, Berkeley), Xiaolin Wang(Macau University of Science and Technology), Jose M. Pacheco(University of Colorado Cancer Center), Anna Capasso(The University of Texas at Austin), Ariel Chen(Revolution Medicines (United States)), Serena Masciari(AVEO Oncology (United States)), Zhengping Wang(Shandong University), Judy S. Wang(Sarah Cannon)
Cited by 16
Related Papers
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k